Gain Therapeutics, Inc.
Using an AI platform to develop allosteric therapies for neurodegenerative diseases.
GANX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US36269B1052
- LEI:
- Country:
- United States of America
- Address:
- 4800 HAMPDEN LANE, 20814 BETHESDA
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Gain Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation allosteric small molecule therapies for disorders with high unmet medical needs. The company's proprietary Magellan™ drug discovery platform combines artificial intelligence, 3D structural biology, and supercomputer-powered physics-based models to identify novel allosteric binding sites on disease-implicated proteins. This approach aims to modulate protein function in ways not achievable with current technologies. The company's lead drug candidate, GT-02287, is in clinical development for the treatment of GBA-Parkinson's disease and other neurodegenerative diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Gain Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Gain Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Gain Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
